[{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Hims & Hers Health, Inc."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hybrid Medical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Hybrid Medical","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Hybrid Medical"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities LLC"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Petros Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.

                          Brand Name : H100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 03, 2022

                          Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 19, 2022

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Endo Pharm

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 24, 2022

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 30, 2021

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Katalyst Securities LLC

                          Deal Size : $10.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for t...

                          Brand Name : H100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 08, 2021

                          Lead Product(s) : Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Hybrid Medical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 03, 2021

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Hims & Hers Health, Inc.

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 19, 2021

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Katalyst Securities

                          Deal Size : $5.7 million

                          Deal Type : Public Offering

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 27, 2021

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for po...

                          Brand Name : Stendra

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 13, 2021

                          Lead Product(s) : Avanafil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank